Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Shares Issued (2016 - 2025)

Aytu Biopharma has reported Shares Issued over the past 14 years, most recently at $14.8 million for Q2 2025.

  • Quarterly Shares Issued rose 338.92% to $14.8 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $18.2 million through Jun 2025, up 146.8% year-over-year, with the annual reading at $14.8 million for FY2025, 328.04% up from the prior year.
  • Shares Issued was $14.8 million for Q2 2025 at Aytu Biopharma, up from $3.4 million in the prior quarter.
  • Over five years, Shares Issued peaked at $14.8 million in Q2 2025 and troughed at -$1.0 million in Q2 2022.
  • The 5-year median for Shares Issued is $3.4 million (2024), against an average of $4.9 million.
  • The largest YoY upside for Shares Issued was 3292.83% in 2022 against a maximum downside of 112.74% in 2022.
  • A 5-year view of Shares Issued shows it stood at $4.5 million in 2021, then tumbled by 74.39% to $1.2 million in 2022, then skyrocketed by 121.52% to $2.6 million in 2023, then skyrocketed by 31.92% to $3.4 million in 2024, then soared by 338.92% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Shares Issued are $14.8 million (Q2 2025), $3.4 million (Q2 2024), and $2.6 million (Q2 2023).